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Background and purpose: 27 
Free fatty acid receptor 1 (FFA1) and FFA4 are located on enteroendocrine L cells with the 28 
highest gastrointestinal (GI) expression in descending colon.  Their activation causes the release of 29 
glucagon-like peptide 1 and peptide YY (PYY) from L cells.  Additionally, FFA1 agonism 30 
releases insulin from pancreatic β-cells.  As these receptors are modulators of nutrient-stimulated 31 
glucose regulation, this study’s aim was to compare the pharmacology of commercially available 32 
agonists (TUG424, TUG891, GW9508) with proven selective agonists (JTT, TAK-875, AZ423, 33 
Metabolex-36), in the mouse.  34 
Experimental approach: 35 
Mouse (>10 weeks old; C57BL/6J) mucosa was mounted in Ussing chambers, voltage-clamped 36 
and the resultant short-circuit current (Isc) recorded continuously.  The pretreatments included 37 
FFA1 antagonists or Y1 ± Y2 antagonists.  Glucose-sensitivity was investigated by mannitol 38 
replacement apically and colonic and upper GI transit was assessed in vitro and in vivo.  39 
Key Results: 40 
FFA1 and FFA4 agonism required glucose and reduced Isc in a PYY-Y1-dependent manner.  The 41 
novel compounds were more potent than GW9508. The FFA1 antagonists (GW1100 and 42 
ANT825) blocked FFA1 activity only and revealed FFA1 tonic activity.  The FFA4 agonist, 43 
Metabolex-36 slowed colonic transit in vitro but increased intestinal transit in vivo.   44 
Conclusion and Implications: 45 
The selective FFA1 and FFA4 agonists were more potent than GW9508, a dual FFA1 and FFA4 46 
agonist. We found that a PYY-Y1 paracrine epithelial mechanism mediated their responses which 47 
were glucose-sensitive, potentially limiting hypoglycaemia. ANT825 revealed tonic activity and 48 
the possibility of endogenous FFA1 ligands causing PYY release.  Finally, FFA4 agonism induced 49 
regional differences in transit. 50 
Keywords:  Free fatty acid receptors 1 and 4, peptide YY, glucagon-like peptide 1, mucosal ion 51 
transport, colonic transit 52 
 53 
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Abbreviations  55 
ANOVA, analysis of variance; 56 
ap, Apical; 57 
AZ, AstraZeneca; 58 
BIBO, BIBO3304; 59 
BIIE, BIIE0246;   60 
bl, Basolateral; 61 
CCK, Cholecystokinin; 62 
CNS, Central Nervous System; 63 
DMSO, dimethyl sulphoxide;  64 
FFA, free fatty acid; 65 
FFA1, free fatty acid receptor 1; 66 
FFA4, free fatty acid receptor 4; 67 
GI, gastrointestinal;  68 
GIP, Gastric inhibitory peptide; 69 
GLP-1, glucagon-like peptide 1; 70 
GLP-2, glucagon-like peptide 2; 71 
GPCR, G protein-coupled receptor; 72 
GSIS, Glucose stimulated insulin secretion; 73 
HPMC, Hydroxylpropyl methylcellulose; 74 
i.p., Intraperitoneal; 75 
Isc, Short-circuit-current; 76 
KH, Krebs Henseleit; 77 
KO, Knockout; 78 
MC4 receptor, Melanocortin-4 receptor; 79 
Met-36, Metabolex-36; 80 
MMC, Myoelectric migrating complex;  81 
OXM, oxyntomodulin;  82 
Phlor, Phloridzin; 83 
PLC, Phospholipase C;  84 
PVP, polyvinylpyrrolidinone; 85 
PYY, peptide YY;  86 
PYY (3-36), peptide YY(3-36); 87 
  4 
SDS, sodium dodecyl sulfate; 88 
SGLT1, Sodium-glucose co-transporter 1; 89 
SST, Somatostatin; 90 
T2DM, type 2 diabetes mellitus; 91 
UGIT, Upper gastrointestinal transit; 92 
VIP; vasoactive intestinal polypeptide; 93 
WT, wild type 94 
 95 
Introduction  96 
Free fatty acid receptors 1 (FFA1, previously known as GPR40) and 4 (FFA4, previously known 97 
as GPR120) are modulators of nutrient-stimulated glucose regulation and therefore are therapeutic 98 
targets for the treatment of type 2 diabetes mellitus (T2DM).  FFA1 selective agonists have been 99 
shown to cause glucose-sensitive insulin secretion (Tsujihata et al. 2011).  FFA1 and FFA4 were 100 
deorphanised in 2003 and 2005 respectively, as receptors for medium to long chain unsaturated 101 
fatty acids (Hirasawa et al. 2005, Itoh et al. 2003).  As endogenous free-fatty acids (FFAs) often 102 
activate more than one receptor type (Kostenis 2004) and are metabolised to act as intracellular 103 
signalling molecules (Warnotte et al. 1994), they have limited utility as selective tools to establish 104 
the pharmacology and functional significance of specific FFA receptors.  The recent discovery of 105 
selective, small molecule agonists for FFA1 and FFA4 therefore provided a pharmacological 106 
advantage over non-selective endogenous FFAs and this study set out to utilise some of these new 107 
tool compounds to investigate FFA1 and FFA4 signalling specifically.  108 
Apart from FFA1 and FFA4 there are alternative FFA receptors in the gastrointestinal (GI) tract 109 
including, FFA2 (formerly GPR43), FFA3 (GPR41) and the acylethanolamide receptor, GPR119, 110 
all of which are selectively expressed in L cells together with FFA1 and FFA4 (Overton et al. 111 
2006, Hirasawa et al. 2005, Edfalk et al. 2008, Karaki et al. 2006).  Both FFA1 (Briscoe et al. 112 
2003) and FFA4 (Hirasawa et al. 2008) have the capacity to couple to Gαq/11, activate 113 
phospholipase C (PLC) and elevate Ca2+ levels, leading to the release of L cell peptide hormones.  114 
Colonic L cells contain peptide YY (PYY), the incretin glucagon-like peptide 1 (GLP-1) plus 115 
GLP-2 and oxyntomodulin (OXM) (Habib et al. 2013, Egerod et al. 2012, Cho et al. 2014).  116 
Additionally, small intestine L cells express neurotensin and cholecystokinin (CCK) (Egerod et al. 117 
2012, Habib et al. 2013).  In this study, we utilised the descending colon because this colonic 118 
region exhibits a greater degree of PYY-Y1 signalling compared with the ascending colon (Cox et 119 
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al. 2001) and L cell density is greater in the distal colon in mouse (Arantes and Nogueira 1997) 120 
and human (Adrian et al. 1985).  GLP-1 slows gastric emptying and enhances satiety (Little et al. 121 
2006) while PYY is a well-known mediator of the ileal and colonic brake (Lin et al. 1996) and a 122 
major satiety-inducing agent together with its product, PYY(3-36) (Batterham et al. 2002).  PYY is 123 
also a significant inhibitor of intestinal epithelial ion transport and we have previously utilised this 124 
activity to monitor the acute endogenous peptide functionality following L cell-specific 125 
stimulation with GPR119 agonists (Cox et al. 2010, Patel et al. 2014) or other L cell mediated 126 
mechanisms (Joshi et al. 2013, Panaro et al. 2014).  In mouse and human distal colon, local 127 
mucosal PYY antisecretory actions are predominantly mediated via epithelial Y1 receptors with a 128 
smaller component of submucosal neuron Y2 activity (Tough et al. 2006, Tough et al. 2011), that 129 
together underpin endogenous PYY paracrine responses.  FFA1 and FFA4 are also potential 130 
nutrient-sensing receptors in L cells and therefore are possible targets for the treatment of T2DM 131 
and obesity (Engelstoft et al. 2008). 132 
The FFA1 agonist TAK-875 (Negoro et al. 2010), which in phase II trials lowered blood glucose 133 
without apparently increasing GLP-1 levels, was shown to signal via Gαq/11 alone, in a manner 134 
similar to the proposed endogenous agonist, α-linolenic acid.  In type II diabetic rats, TAK-875 135 
improved glucose tolerance and enhanced glucose-dependent insulin secretion (Tsujihata et al. 136 
2011). Despite the liver toxicity concerns of TAK-875, it significantly improved glycaemic 137 
control in diabetic Japanese patients in a phase III study (Kaku et al. 2015).     JTT, a novel 138 
selective FFA1-targeted agonist (from patent number, WO 2009/054479), TAK-875 and the 139 
commercially available FFA1 agonist, TUG424 (Christiansen et al. 2008) were selected to assess 140 
the pharmacology of FFA1 in this study. 141 
 142 
FFA4 is also found abundantly in gastric-inhibitory peptide (GIP)-containing K cells of the small 143 
intestine, gastric somatostatin (SST)-containing D cells and gastric ghrelin-containing A cells (Ito 144 
et al. 2009, Parker et al. 2009, Engelstoft et al. 2013, Egerod et al. 2015).  The functional roles of 145 
FFA4 include enhanced insulin secretion, GLP-1 secretion (Halder et al. 2013), reduced gastric 146 
emptying (Little et al. 2006) and anti-inflammatory effects (Oh et al. 2010).  FFA4 knockout (KO) 147 
mice exhibited a significantly reduced L cell GLP-1 secretion (Xiong et al. 2013) and K cell GIP 148 
secretion (Iwasaki et al. 2015) indicating that signalling via FFA4 in wild type (WT) tissues can 149 
cause incretin peptide release.  The novel selective agonists selected for this study, AZ423 150 
(Compound 34, McCoull et al. 2017) and Metabolex-36 (Ma et al. 2010), show 100-fold 151 
selectivity for murine FFA4 compared with FFA1 (Stone et al. 2014).  Furthermore, AZ423 and 152 
  6 
Metabolex-36 have exhibited a reduction in blood glucose excursion in an oral glucose tolerance 153 
test (Halder et al. 2013, McCoull et al. 2017).  Additionally, the selected commercially available 154 
FFA4 agonist, TUG891 is selective for murine and human FFA4 (Hudson et al. 2013).  Whether 155 
intestinal FFA4 agonism resembles FFA1 activities and is also glucose-sensitive in 156 
enteroendocrine L cells has yet to be determined. 157 
 158 
As few functional studies have been performed in native preparations containing L cells, one aim 159 
of this study was to determine the potencies and efficacies of the commercially available agonists 160 
(TUG424 and TUG891) compared with the non-selective FFA1 and FFA4 agonist GW9508, and 161 
importantly the novel selective agonists JTT, TAK-875, AZ423 and Metabolex-36 in mouse 162 
colon.  We also assessed the selectivity of the FFA1-preferring antagonist GW1100 (Briscoe et al. 163 
2006) comparing it with ANT825, a selective FFA1 antagonist (referred to as compound 39 in 164 
Waring, 2015) and determined their relative abilities to reveal tonic FFA1 activity.  We also 165 
determined the involvement of endogenous PYY in these responses in colonic mucosae by 166 
blocking peptide activity pharmacologically.  Finally, the effects of FFA1 and FFA4 agonism 167 
upon colonic motility in vitro and in vivo were established.  168 
 169 
Methods 170 
Mucosal preparation and Isc measurement 171 
Mice (C57BL/6J, 12-20 weeks old, 20-30g, female and male) were procured from Charles River 172 
Laboratories (Margate, UK) had free access to standard chow (Rat and Mouse No 3 breeding diet, 173 
Special Diets Services, Braintree, UK) and water ad libitum. We used mice because the Y1, Y2 and 174 
Y4 receptor localisation in the GI tract is the same in this species as in human colon (Cox and 175 
Tough. 2001, Tough et al. 2011).  Mice were housed in open top conventional cages with Lignocel 176 
poplar bedding material along with the appropriate environmental enrichment.  A maximum of 5 177 
mice were housed in a single cage. Housing rooms were maintained at 20-24 ◦C, humidity 55% ± 178 
10% and 12/12 h light and dark cycle. All animal care and experimental procedures complied with 179 
the Animals (Scientific procedures) Act 1986 and were approved by UK Home Office (licence 180 
number: PPL70/7887).  Mice were killed by cervical dislocation and the whole colon was 181 
dissected (noting proximal and distal ends) and placed in fresh Krebs-Henseleit (KH), with the 182 
following composition (in mM); NaCl 118, KCl 4.7, NaHCO3 25, KH2PO4 1.2, MgSO4 1.2, CaCl2 183 
2.5, and D-glucose 11.1.  Mucosae from the descending colon were prepared by removing the 184 
  7 
overlying smooth muscle layers and associated myenteric plexi by micro-dissection.  Mucosal 185 
lengths were cut in to 4-6 adjacent pieces, each of which was mounted between two halves of an 186 
Ussing chamber (WPI UK, Hitchin, Herts, UK) (exposed area, 0.14 cm2), voltage-clamped at 0 187 
mV (DVC1000 and amplifiers; WPI UK, Hitchin, Herts, UK) and equilibrated in oxygenated KH 188 
(95% O2/5% CO2, at 37˚C) for 15 min. Drug additions were made to either the basolateral (bl) or 189 
apical (ap) reservoirs and changes in short-circuit current (Isc) were measured continuously.  190 
 191 
Sidedness, potency and efficacy of the FFA1 and FFA4 compounds 192 
Mucosae were pretreated with vasoactive intestinal polypeptide (VIP, 30 nM, bl) to provide a 193 
degree of vectorial epithelial ion secretion upon which subsequent antisecretory signalling is more 194 
readily observed (as optimised previously; Tough et al. 2006; Cox et al. 2010).  Once VIP 195 
responses had reached a maximum, a FFA1 or FFA4 agonist (TUG424 (300 nM), TUG891 (300 196 
nM), GW9508 (10 μM)) was added to either reservoir as indicated, to determine the approximate 197 
sidedness of the FFA1 and FFA4 responses.  Single additions of apical FFA1 or FFA4 agonists 198 
were used to construct concentration-response curves and calculate single EC50 values with 199 
GraphPad Prism v6.0.  Changes in Isc to certain FFA1 agonists (TAK-875, JTT and GW9508) and 200 
FFA4 agonists (Metabolex-36, AZ423) were biphasic; the first component (1˚) being a transient 201 
increase in Isc (within 5 min) followed by a longer-lasting reduction in Isc (the second component, 202 
2˚) that was extrapolated from the waning VIP signal and reached its maximum within 10-15 min 203 
of FFA drug addition.  When the biphasic changes in Isc were observed, the 1˚ and 2˚ components 204 
were analysed separately.  To investigate whether there was a neuronal component to FFA1 205 
(TAK-875, 200 nM) and FFA4 (Metabolex-36, 100 nM) signalling, mucosae were pretreated with 206 
the neurotoxin, tetrodotoxin (TTX, 100 nM, bl) or vehicle (H2O) for 15 min, followed by VIP and 207 
subsequently the FFA1 or FFA4 agonist. The responses to TAK-875 and Metabolex-36 were 208 
monitored for 20 min and finally PYY (10 nM, bl) was added as an internal control.  Changes in 209 
Isc to each drug or peptide were pooled and converted to µA.cm
-2.  210 
 211 
Establishing the selectivity of FFA1 and FFA4 agonism using antagonists 212 
In order to establish an IC50 of the FFA1 antagonist, ANT825, basal Isc levels were allowed to 213 
stabilise before the addition of varying single concentrations (1 nM - 10 µM) of the FFA1 214 
antagonist.  After 10-15 min, VIP was added, followed by the selected FFA1 agonist, JTT (300 215 
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nM) and consequent reductions in Isc were recorded and converted to µA.cm
-2.  PYY (10 nM) was 216 
added finally as an internal control.  The antagonist concentration (10 µM, ANT825) that 217 
abolished JTT responses was used in subsequent selectivity studies.  218 
Blockade of the commercially available FFA1 agonists (TUG424, GW9508 and TAK-875) was 219 
confirmed using the antagonists, GW1100 (10 µM) (Briscoe et al. 2006) and ANT825 (10 µM).  220 
Here mucosae were pretreated apically for 10 min with the appropriate vehicle (0.1% DMSO) or 221 
the chosen FFA1 antagonist prior to VIP addition.  TUG424 (100 nM), GW9508 (1 µM) were the 222 
FFA1 agonists tested initially, followed by TAK-875 (200 nM) and JTT (300 nM) while TUG891 223 
(100 nM), Metabolex-36 (100 nM) and AZ423 (100 nM) were used to preferentially activate 224 
FFA4 receptors unless otherwise quoted.  Finally, PYY (10 nM) was added as an internal control. 225 
ANT825 was chosen as the preferred FFA1 antagonist in further studies. 226 
 227 
Y1 and Y2 receptor antagonist (BIBO3304 and BIIE0246) studies 228 
Tissues were pretreated with previously optimised concentrations of the Y1 antagonist, BIBO3304 229 
(BIBO, 300 nM, bl) or the Y2 antagonist, BIIE0246 (BIIE, 1 µM, bl) or both, versus their 230 
respective DMSO (0.003-0.1 %) controls.  After 10-15 min VIP was added and once this response 231 
had stabilised, a single apical concentration of the FFA1 or FFA4 agonists was added and the 232 
consequent reduction in Isc was converted to µA.cm
-2.  PYY and the α2-adrenoceptor agonist, 233 
UK14,304 (1 µM) were used as internal controls. 234 
 235 
Mucosal glucose-sensitivity studies 236 
Excised whole colon was placed in fresh glucose-free KH with the following composition (in 237 
mM); NaCl 118, KCl 4.7, NaHCO3 25, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, and D-mannitol 11.1.  238 
Mucosae were dissected as described above, placed in Ussing chambers and were bathed in KH 239 
containing glucose on both sides or replacing glucose with mannitol (at 11.1 mM) on the ap side 240 
only.  When investigating FFA1 and FFA4 agonism in the presence of lower or higher glucose; 241 
the glucose concentration was altered (either 5 mM or 25 mM in KH) on ap and bl sides 242 
simultaneously.  Mucosal basal Isc levels were allowed to stabilise before the addition of VIP and 243 
once stabilised, a single apical addition of the FFA1 or FFA4 agonists was added and consequent 244 
reductions in Isc were recorded and converted to µA.cm
-2.  Phloridzin (50 µM, ap), the sodium-245 
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glucose co-transporter 1 (SGLT1) inhibitor was used to block apically located SGLT1 and this 246 
electrogenic response should be lost when mannitol replaced apical glucose.  247 
  248 
Faecal pellet propulsion in vitro 249 
The colon (from the caeco-colonic junction to the rectum) was excised, photographed (t = 0 min) 250 
and bathed in KH at 37˚C with either vehicle (0.1% DMSO) or agonist (300 nM TUG424, 251 
TUG891, TAK-875 or Metabolex-36) as indicated.  After 20 min (t = 20 min) each colon length 252 
was re-photographed and the distance travelled by the remaining pellets was measured from the 253 
rectum, as described previously (Tough et al. 2011).  The effects on transit of the agonists were 254 
compared in the absence and presence of the FFA1 antagonist, GW1100 (10 µM).  In these 255 
experiments, the colon was bathed in vehicle (0.1% DMSO) or antagonist, photographed at 20 256 
min, and then bathed in KH containing the agonist of choice for 20 min.  The colon was re-257 
photographed at t = 40 min.  The pellet movement was measured as mean distance travelled 258 
relative to the total colonic length and was used to calculate the % colonic transit.  259 
 260 
Colonic bead excretion in vivo 261 
Mice were acclimatised to handling 3 days prior to experimentation and were fasted 16 h prior to 262 
testing, although water was provided ad libitum.  Plasma glucose before the fast was 10.5 ± 0.9 263 
mmol/l (mean ± 1 SEM, n=9) and 4.8 ± 0.3 mmol/l after fasting (n=9).  Distal colonic propulsion 264 
was measured according to the methods described by Forbes et al (2012).  One hour after 265 
administration of vehicle, or drug (FFA1 agonist, TAK-875; FFA4 agonist, Metabolex-36, FFA1 266 
antagonist, ANT825) or the positive control (loperamide hydrochloride (HCl) by oral gavage or 267 
intraperitoneal (i.p.) injection, mice were placed under 4-5% isoflurane anaesthesia (Isoflurane-268 
VET, Merial Animal Health Ltd, Harlow, UK) and a 2 mm bead was inserted 2 cm intrarectally 269 
into the distal colon using blunt tubing (Portex, 1.7 × 0.4 mm).  The mice were subsequently 270 
placed into a grid bottom cage, monitored and the time to bead expulsion was measured. Once the 271 
bead was excreted, the mouse was killed by cervical dislocation.  All drugs were suspended in 272 
their respective vehicles and sonicated for 30 min.   273 
 274 
Upper GI transit in vivo 275 
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Mice were acclimatized to handling 3 days prior to experimentation and were fasted for 16 h prior 276 
to testing.  TAK875, Metabolex-36, ANT825, their respective vehicles or loperamide HCl was 277 
administrated via i.p. injection, 60 min prior to testing. In the experiments that used the SST2 278 
antagonist, CYN 154806, mice were pretreated with the antagonist (3 mg/kg) or saline for 15 min, 279 
prior to Metabolex-36 (50 mg/kg, i.p.).    A charcoal meal (10% plant charcoal in 5% gum acacia 280 
(Tough et al. 2011)) was given by intragastric gavage, and 30 min later the animal was killed by 281 
cervical dislocation and the small intestine was isolated from the pyloric to ileocecal junctions.   282 
Upper GI transit (UGIT), encompassing gastric emptying and small intestinal motility was 283 
determined as previously described (Forbes et al. 2012). 284 
 285 
Statistical analysis 286 
Pooled responses (as µA.cm-2) are expressed as mean ± SEM from the numbers of observations as 287 
shown, using GraphPad Prism version 6.0 (GraphPad Prism Inc., La Jolla, CA, USA).  Single 288 
comparisons between groups of data were analysed by unpaired, two-tailed Student's t-tests or 289 
one-way ANOVA for multiple comparisons with post hoc Dunnett’s test.  Post hoc tests were run 290 
only when F achieved P < 0.05 and there was no significant variance inhomogeneity.   P < 0.05 291 
was considered statistically significant. Mice (males and females) were randomised in this study.  292 
Additionally, drug treatments added to each mucosal preparation were randomised using the Latin 293 
square design technique. Furthermore, vehicle and drug treatments were alternated in the in vivo 294 
studies for each cohort.  Explicit blinding was not performed however; each repeat was compared 295 
with one another and the drug-pretreated repeats. Any discrepancies between n number cohorts 296 
were due to the loss of a single mucosal preparation from a single animal in vitro, or a value was 297 
removed when it was more than two standard deviations from the mean in vitro and in vivo. The 298 
data and statistical analyses comply with the recommendations on experimental design and 299 
analysis in pharmacology (Curtis et al. 2015).   300 
 301 
Materials 302 
FFA1 (JTT and TAK-875) and FFA4 agonists (AZ423 and Metabolex-36) and the FFA1 303 
antagonist (ANT825) were obtained from AstraZeneca, Gothenburg, Sweden.  Stock solutions of 304 
drugs were dissolved in neat DMSO (at 10-2 M or 10-3 M).  Initial 1:10 dilutions were in neat 305 
DMSO and subsequent serial dilutions were in distilled water (excluding the FFA1 agonist, TAK-306 
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875 and the FFA4 agonist, AZ423, where all serial dilutions were performed in distilled water).  307 
BIBO3304, (N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-308 
[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamide ditrifluoroacetate), BIIE0246, (N-309 
[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-310 
yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-311 
piperazinyl]-2-oxoethyl]-cyclopentaneacetamide), GW9508 (4-[[(3-312 
Phenoxyphenyl)methyl]amino]benzenepropanoic acid), TUG424, (3-(4-(o-313 
Tolylethynyl)phenyl)propanoic acid), TUG891 (4-[(4-Fluoro-4'-methyl[1,1'-biphenyl]-2-314 
yl)methoxy]-benzenepropanoic acid) and CYN 154806 (Ac-(4-NO2-Phe)-cyc(D-Cys-Tyr-D-Trp-315 
Lys-Thr-Cys)-D-Tyr-NH2) were purchased from Tocris Bioscience (Bristol, UK).  GW1100 (4-[5-316 
[(2-ethoxy-5-pyrimidinyl)methyl]-2-[[(4-fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-317 
benzoic acid,ethyl ester) and loperamide HCl was from Cambridge Bioscience (Cambridge, UK).  318 
VIP and PYY were purchased from Cambridge Bioscience (Cambridge, UK) and TTX from 319 
Abcam, (Cambridge, UK).  VIP, PYY and TTX were dissolved in distilled water.  All peptide 320 
stocks were stored at -20˚ C until required and underwent a single freeze-thaw cycle.   Phloridzin 321 
(1-[2-(β-D-glucopyranosyloxy)-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl]-1-propanone) was 322 
purchased from Sigma-Aldrich (Dorset, UK) and it too was dissolved in distilled water.  The 323 
following in vivo vehicles were all suspended in warm saline, methylcellulose and 324 
polyvinylpyrrolidinone (PVP) from Sigma-Aldrich (Dorset, UK), sodium dodecyl sulfate (SDS) 325 
from VWR International (Leicestershire, UK), hydroxylpropyl methylcellulose (HPMC) from 326 
Alfa Aesar (Lancashire, UK) and Tween-80 from Boston BioProducts (Ashland, USA).  327 
 328 
Nomenclature of Targets and Ligands  329 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 330 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide 331 
to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide 332 
to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 333 
 334 
Results    335 
The sidedness, potency and efficacy of FFA1 and FFA4 agonists in descending colon mucosa 336 
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First, basal resistance and Isc levels after stabilisation of the colonic mucosae were within ranges 337 
published previously (Figure 1A) (Tough et al. 2011).  The activity of the non-selective FFA1 and 338 
FFA4 agonist, GW9508 (Figure 1B), as well as the TUG compounds added apically or 339 
basolaterally induced a biphasic change in Isc.  When the reductions in Isc were compared, there 340 
were no significant differences between the response sizes to each agonist added to either side 341 
(Figure 1C).  The more selective FFA1 agonists, TAK-875 and JTT and FFA4 agonists, 342 
Metabolex-36 and AZ423 were added apically and induced a biphasic Isc response.  The rapid first 343 
Isc component was attributed to the vehicle, 0.1% DMSO (3.0 ± 1.1 µA.cm
-2, n=12) when 344 
compared with the same component for JTT (1.7 ± 0.9 µA.cm
-2, n=5) and Metabolex-36 (3.2 ± 1.7 345 
µA.cm-2, n=4) or 0.01% DMSO (3.0 ± 1.1 µA.cm-2, n=6) when compared with TAK-875 (2.5 ± 346 
1.3 µA.cm-2, n=6) and AZ423 (4.6 ± 1.4 µA.cm-2, n=6).  Only the later reductions in Isc to varying 347 
concentrations of each FFA1 and FFA4 agonists are shown in Figure 1 D - F. To determine 348 
whether the FFA1 and FFA4 responses were neuronal, we pretreated the mucosae with TTX (100 349 
nM, bl). The responses to TAK-875 (-11.2 ± 2.0 µA.cm-2, n=5) and Metabolex-36 (-8.3 ± 2.3 350 
µA.cm-2, n=5) were unaffected by TTX compared to their DMSO controls (-7.5 ± 1.8 µA.cm-2 and 351 
-8.1 ± 2.2 µA.cm-2 respectively, n=5), indicating FFA1 and FFA4 responses are most likely 352 
epithelial in origin and their responses are not mediated by TTX-sensitive neurons. 353 
The reductions in Isc to each agonist were concentration-dependent, with TUG424 and TUG891 354 
being similarly potent, approximate EC50 values were 57.1 nM (24.7 – 131.8 nM) and 62.5 nM 355 
(24.1 – 162.3 nM) respectively (Figure 1D).  GW9508 was less potent with an EC50 value of 354.8 356 
nM (191.6 – 656.8 nM) and appeared to be slightly more efficacious; however, this was not 357 
significantly different from the TUG agonists (Figure 1D) or the selective FFA1 or FFA4 agonists.  358 
JTT was more potent (EC50 of 20.7 nM (12.7 – 34.0 nM)) than TAK-875 (EC50 of 67.6 nM (30.6 – 359 
149.4 nM)) and they exhibit similar efficacy (Figure 1E). Furthermore, the FFA4 agonist 360 
Metabolex-36 (EC50 of 15.4 nM (7.9 – 30.4 nM)) and AZ423 (EC50 of 17.3 nM (3.6 – 83.8 nM)) 361 
were similarly potent and efficacious (Figure 1F). In comparison to the selective FFA1 and FFA4 362 
agonists, GW9508 appeared to be a dual agonist.   363 
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 364 
Figure 1. FFA1 and FFA4 responses in descending colon mucosa.  In A: basal Isc and 365 
resistance values after stabilisation of mucosal preparations (n=20). In B: representative trace 366 
showing the biphasic nature of apical GW9508 (10 µM) response in descending colon mucosa 367 
after VIP (30 nM) and followed by PYY (10 nM).  In C: pooled data showing the primary (1˚) and 368 
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secondary (2˚) responses to apical (ap) or basolateral (bl) additions of GW9508 (n=5), TUG424 369 
(n=5) or TUG891 (n=5).  The 1˚ responses were recorded within 0-5 min of agonist addition (and 370 
were due to vehicle), whereas 2˚ reductions in Isc occurred within 10-15 min.  Concentration-371 
response curves for the 2˚ effects of TUG424 (n=5 for all concentrations, except 300 nM (n=6)) 372 
and TUG891 (n=5) compared with GW9508 (n=5) shown in grey in D; for JTT (n=5) and TAK-373 
875 (10 nM (n=5), 30 nM (n=5), 100 nM (n=6), 300 nM (n=5), 1 µM (n=7) and 3 µM (n=8)) in E; 374 
and AZ423 (n=5) and Metabolex-36 (n=5) in F.  Bars and points are the means ± 1SEM.  375 
 376 
GW1100 and ANT825 each inhibit agonist-induced FFA1 responses in the descending colon 377 
The FFA1 antagonists, GW1100 and ANT825 alone revealed a similar degree of FFA1 tonic 378 
activity under basal conditions in the distal colon (Figure 2A).  ANT825 inhibited JTT responses 379 
competitively (Figure 2B), with an IC50 of 219 nM.  Optimal blocking concentrations of each 380 
FFA1 antagonist, GW1100 or ANT825 revealed the selectivity of TUG424 and GW9508 for the 381 
FFA1 receptor.  TUG891 responses were not affected by either FFA1 antagonist.  Additionally, 382 
only part of the GW9508 response was reduced in the presence of ANT825 or GW1100 (Figure 383 
2C).  The FFA1 selective agonists (TAK-875 and JTT) were significantly inhibited by ANT825 384 
whereas the FFA4 selective agonists, Metabolex-36 and AZ423 responses were unaffected (Figure 385 
2D).  386 
 387 
 388 
 389 
 390 
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  392 
Figure 2. Tonic FFA1 activity and inhibition of FFA1 responses by GW1100 or ANT825.  In 393 
A: changes in Isc to vehicle, DMSO or the FFA1 antagonists, GW1100 or ANT825 alone.  In B: 394 
competitive inhibition of the FFA1 agonist, JTT responses by pretreatment with the FFA1 395 
antagonist, ANT825.  Each point is the mean ±1SEM (n=5 for all concentrations of JTT except 10 396 
µM (n=6)).  In C: pooled data shows the selective inhibition of apical TUG424 and GW9508 397 
responses, but not TUG891 responses following apical GW1100 or ANT825 treatment compared 398 
with respective vehicle controls (+DMSO controls for TUG424 (n=6), for TUG891 (n=5) and for 399 
GW9508 (n=5)).  In D: selective inhibition of the FFA1 agonists TAK-875 and JTT responses but 400 
not the FFA4 agonist, AZ423 and Metabolex-36 (Met-36) responses following apical ANT825 401 
treatment (10 µM, n=5).  Statistical differences from respective vehicle controls are shown as 402 
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follows; * P < 0.05 (Student's t test) and + P < 0.05 (one-way ANOVA with Dunnett’s post hoc 403 
test).   404 
 405 
FFA1 and FFA4 colonic responses are BIBO3304 but not BIIE0246 sensitive 406 
Endogenous PYY mediation of the FFA1 (JTT and TAK-875) and FFA4 (AZ423 and 407 
Metabolex-36) agonist responses were determined by blocking with the Y1 antagonist, 408 
BIBO3304, the Y2 antagonist, BIIE0246 or both antagonists together.  Each antagonist 409 
revealed endogenous PYY-Y1 and Y2 tonic activity under basal conditions (Figure 3A) 410 
similar to that observed in the mouse colon previously (Tough et al. 2011, Hyland et al. 411 
2003).  FFA1 responses to JTT (Figure 3B) and TAK-875 (Figure 3C) were abolished by the 412 
Y1 antagonist, indicating PYY-Y1 signalling predominantly mediates FFA1 responses.  The 413 
FFA1 responses in the presence of the Y2 antagonist were slightly reduced, suggestive of a 414 
minor role for Y2 receptors as seen previously (Tough et al. 2011).  Notably, there was no 415 
influence of the Isc level at the time of adding the FFA1 agonist on subsequent FFA1 416 
efficacy.  Taken together these observations confirm selective Y1-mediation of FFA1 417 
responses.  Subsequent exogenous PYY responses were also abolished by the Y1, but not by 418 
the Y2 antagonist alone, while the combination abolished PYY activity (Figure 3D).  The 419 
responses to FFA4 agonists, AZ423 (Figure 3E) and Metabolex-36 (Figure 3F) were also 420 
abolished by the Y1 but not Y2 antagonist and thus both FFA1 and FFA4 responses in the 421 
mouse colon are Y1 receptor mediated. 422 
 423 
 424 
 425 
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 426 
Figure 3. Y1- but not Y2-receptor sensitivity of FFA1 and FFA4 agonism in the descending 427 
colon. The effects of the Y1 (BIBO3304, BIBO, 300 nM) ± the Y2 (BIIE0246, BIIE, 1 µM) 428 
antagonist and corresponding DMSO controls (+.003 %, +.01 %, +.013 %) on baseline Isc levels 429 
are shown in A.  The effect of the FFA1 agonists, JTT (n=5 for all data groups except +.003% and 430 
+.013% (n=6)) and TAK-875 (n=5 for all data groups except +BIBO (n=6)) in the absence or 431 
presence of Y antagonists are shown in B and C respectively.  Exogenous PYY (10 nM) responses 432 
(n=5 for all data groups except +.003% and +.013% (n=6)) after JTT treatment, in the presence of 433 
DMSO or Y1 ± Y2 antagonists are shown in D.  The FFA4 agonist’s responses, AZ423 (n=5) and 434 
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Metabolex-36 (n=5 for all data groups except +.01% (n=6)) are shown in E and F respectively.  435 
Bars represent the mean ± 1 SEM. Statistical differences between vehicle controls (0.003 %, 0.01 436 
% and 0.013 % DMSO) and respective antagonists BIBO, BIIE or both are shown as follows; * P 437 
< 0.05 (Student's t test).   438 
 439 
FFA1 and FFA4 responses are glucose-sensitive in the descending colon mucosa 440 
In order to establish the glucose-sensitivity of FFA signalling in mucosal preparations, the 441 
responses to the FFA1 and FFA4 agonists were compared in the presence or absence of apical 442 
glucose.  Mannitol replacement of apical glucose abolished the FFA1 responses (Figure 4A & B) 443 
and inhibited FFA4 activity (Figure 4C & D) compared to vehicle.  Internal controls using 444 
phloridzin (Phlor, added ap) decreased the Isc, but as expected only in the presence of glucose 445 
(because SGLT1 requires glucose to function and is targeted apically).  Thus, FFA1 and FFA4 446 
receptors can be activated in a glucose-sensitive manner.  In contrast, PYY responses were not 447 
glucose-sensitive (Figure 4A-D).  Furthermore, TAK-875 and Metabolex-36 responses were not 448 
affected when the glucose concentration (ap + bl) was varied to represent a hypoglycaemic (5.0 449 
mM) or hyperglycaemic (25.0 mM) environment (Figure 4E).  450 
 451 
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 452 
Figure 4. Glucose-sensitivity of FFA1 and FFA4 agonism in the descending colon.  Glucose-453 
sensitivity of apical FFA1 agonists, JTT (300 nM, n=5) in A, TAK-875 (200 nM, n=5) in B and 454 
apical FFA4 agonists, AZ423 (100 nM, n=5) in C and Metabolex-36 (100 nM, n=5) in D, in the 455 
presence (black bars) and absence (white bars) of 11.1 mM glucose.  Control mucosae were 456 
bathed in glucose both sides whereas, mannitol (+ mann, 11.1 mM) replaced glucose apically 457 
only.  Phloridzin (Phlor, 50µM, apically only) and PYY (10 nM) responses are also shown.  In E: 458 
TAK-875 (200 nM, n=5) and Metabolex-36 (100 nM, n=5) antisecretory responses in the presence 459 
of apical and basolateral (ap + bl) 5.0 mM glucose or 25.0 mM glucose. Bars represent the mean - 460 
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1SEM. Statistical differences between agonist or phloridzin responses in the presence or absence 461 
of glucose, are shown as follows; * P < 0.05 (Student's t test). 462 
 463 
Caeco-colonic transit is inhibited by FFA1 and FFA4 agonists  464 
Since FFA1 and FFA4 mucosal responses in the colon were mediated by PYY and this 465 
endogenous peptide is known to slow colonic transit (Tough et al. 2011), we next assessed 466 
whether the FFA1 and FFA4 agonists reduced transit at single optimal concentrations (300 nM; 467 
Figure 5A).  In isolated colons, TUG424, TUG891, TAK-875 and Metabolex-36 significantly 468 
decreased transit in comparison to vehicle-treated (DMSO, 0.1%) controls.  469 
Since GW1100 (10 µM) inhibited FFA1 responses in colonic mucosa, we set out to determine 470 
whether GW1100 alone could increase basal faecal transit and reverse the effect of the FFA1 471 
agonist on colonic transit, in vitro.   Figure 5B shows that GW1100 alone significantly increased 472 
basal colonic transit, again indicating endogenous FFA1 inhibitory tone.  After 20 min 473 
pretreatment with the FFA1 antagonist, GW1100 the effect of TUG424 and TUG891 was assessed 474 
in the presence and absence of GW1100.  In the presence of GW1100, the inhibitory effect on 475 
colonic transit of TUG424 was reversed, but GW1100 had no effect on TUG891 (FFA4) activity, 476 
showing FFA1 selectivity (Figure 5B). 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
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 504 
 505 
Figure 5. Colonic transit is slowed by FFA1 and FFA4 agonists in isolated colons in vitro. 506 
Colonic transit is slowed by 300 nM of TUG424 (n=6), TAK-875 (n=6), TUG891 (n=6) and 507 
Metabolex-36 (Met-36, n=6) in A at t =20 min.  In B: the effects of FFA1 antagonist GW1100 (10 508 
μM) are compared on basal faecal transit at t=20 min and on subsequent inhibition of transit 509 
following 20 min treatment with TUG424 or TUG891 at t=40 min (n = 5).  Each bar represents 510 
the mean + 1SEM.  Statistically significant differences from controls were; * P < 0.05 (Student's t 511 
test) and + P < 0.05 (one-way ANOVA with Dunnett’s post hoc test).  512 
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 513 
Colonic bead propulsion is slowed by Metabolex-36 not TAK875 or ANT825 in vivo 514 
As the FFA1 and FFA4 agonists, (TAK-875 and Metabolex-36 respectively) slowed transit in 515 
isolated colons in vitro; we assessed the ability of these agonists and loperamide HCl to slow 516 
colonic transit in vivo, comparing oral administration versus i.p. injection.  Additionally, we 517 
investigated whether ANT825 had the potential to reveal FFA1 tone in vivo.  Oral administration 518 
of the positive control, loperamide HCl significantly slowed transit compared to its vehicle 519 
control.  Two doses of Metabolex-36 were assessed orally; the lower dose had no effect on transit 520 
whereas the higher dose significantly slowed transit.  Furthermore, oral gavage of TAK-875 and 521 
ANT825 had no effect on colonic transit (Figure 6A).   Both loperamide HCl and Metabolex-36 522 
significantly slowed colonic transit when given via i.p. injection whereas TAK-875 and ANT825 523 
had no effect (Figure 6B).  As i.p. injection of loperamide HCl slowed transit more efficiently in 524 
comparison to oral gavage, we used this route of administration for each drug in the subsequent in 525 
vivo studies. 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
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 553 
Figure 6. The effect of oral gavage versus i.p. injection of FFA ligands and loperamide HCl 554 
on colonic bead expulsion in vivo.  The effect on colonic bead expulsion (expressed as time until 555 
bead expelled (min)) after oral gavage or i.p. injection of loperamide HCl (10 mg/kg, red bar, 556 
n=11) compared with its vehicle control, 0.5% methylcellulose (blue bar, n=11); the FFA4 557 
agonist, Metabolex-36 at two doses: 6 mg/kg (yellow bar with black horizontal stripes, n=6) and 558 
50 mg/kg (yellow bar with black diagonal stripes, n=10)  compared with their vehicle control, 559 
0.5% hydroxylpropyl methylcellulose (HPMC) + 0.1% Tween-80 (yellow bar, n=10); the FFA1 560 
agonist, TAK-875 (27 mg/kg, blue bar with white diagonal stripes, n=11) compared with its 561 
vehicle control (0.5% methylcellulose, blue bar) and finally the FFA1 antagonist, ANT825 (29 562 
mg/kg, orange bar with white diagonal stripes, n=7) compared with its vehicle (0.25% 563 
polyvinylpyrrolidone (PVP) + 0.05% sodium dodecyl sulfate (SDS), orange bar, n=7).  Each bar 564 
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represents the mean + 1SEM.  Statistically differences from controls were; * P < 0.05 (Student's t-565 
test).  Differences between the oral doses of Metabolex-36 from its control and additionally 566 
between loperamide HCl (i.p.) and the FFA drugs were; + P < 0.05 (one-way ANOVA with 567 
Dunnett’s post hoc test). 568 
 569 
Upper GI transit is increased by Metabolex-36 in vivo 570 
Here we investigated whether the FFA agonists (i.p.) and loperamide HCl could slow intestinal 571 
transit and additionally whether ANT825 could increase intestinal transit (revealing FFA1 tone), 572 
after mice were given a charcoal meal (as described in the methods).  The positive control, 573 
loperamide HCl significantly slowed GI transit, as expected compared to its vehicle control. 574 
Unexpectedly, Metabolex-36 significantly increased intestinal transit whereas TAK-875 and 575 
ANT825 had no effect (Figure 7).  576 
 577 
 578 
 579 
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Figure 7. The effect of an i.p. injection of loperamide HCl and FFA ligands on UGIT in vivo. 590 
The intestinal transit of a charcoal meal (expressed as a percentage of the small intestine length) 591 
after i.p. injection of the positive control, loperamide HCl (10 mg/kg, red bar, n=6) compared with 592 
its vehicle control, 0.5% methylcellulose (blue bar, n=6); the FFA4 agonist, Metabolex-36 (50 593 
mg/kg, yellow bar with black diagonal stripes, n=6) compared with its vehicle control, 0.5% 594 
hydroxylpropyl methylcellulose (HPMC) + 0.1% Tween-80 (yellow bar, n=6); the FFA1 agonist, 595 
TAK875 (27 mg/kg, blue bar with white diagonal stripes, n=5) compared with its vehicle control 596 
(0.5% methylcellulose, blue bar) and the FFA1 antagonist, ANT825 (29 mg/kg, orange bar with 597 
white diagonal stripes, n=5) compared with its vehicle (0.25% polyvinylpyrrolidone (PVP) + 598 
0.05% sodium dodecyl sulfate (SDS), orange bar, n=5).  Each bar represents the mean + 1SEM.  599 
Statistically differences from controls were; * P < 0.05 (Student t-test) whereas differences 600 
between loperamide HCl and FFA drugs were; + P < 0.05 (one-way ANOVA with Dunnett’s post 601 
hoc test). 602 
 603 
SST2 inhibition has no effect on Metabolex-36 induced UGIT effect in vivo 604 
As Metabolex-36 increased UGIT in vivo, we investigated whether this was due to an inhibitory 605 
FFA4 effect (via a Gαi-mediated mechanism) on somatostatin-containing D cells in the GI tract.  606 
This inhibition would result in disinhibition and ultimately a pro-motile effect, as somatostatin is a 607 
known inhibitor of GI motility.  Mice were pretreated with the SST2 antagonist, CYN 154806 or 608 
saline before the effect of Metabolex-36 was tested.  CYN 154806 + Metabolex-36 had no effect 609 
on the UGIT of the charcoal meal, in comparison to mice pretreated with saline (Figure 8). 610 
 611 
 612 
 613 
 614 
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 616 
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Figure 8. CYN 154806 had no effect on the Metabolex-36 induced increase in UGIT in vivo. 626 
The effect of Metabolex-36 (50 mg/kg, i.p. injection) on UGIT in the absence (saline, n=5) or 627 
presence (n=5) of the SST2 antagonist, CYN 154806.  Bars represent mean + 1SEM. 628 
 629 
Discussion  630 
 631 
The improved selectivity of FFA1 and FFA4 agonists versus commercially available agonists 632 
FFA1 and FFA4 agonism was independent of the surface of administration and the time-633 
dependence of Isc changes was similar, suggesting that these receptors are located on both the 634 
apical and basolateral surfaces.  However, it should be noted that all the drugs used were lipid 635 
soluble requiring DMSO as a vehicle therefore, drugs added on the apical surface could activate 636 
FFA receptors on the basolateral side and vice versa.  Interestingly, Christensen et al. (2015) 637 
showed preferential but not exclusive vascular (basolateral) FFA1-induced GLP-1 secretion using 638 
endogenous and synthetic agonists, in rat small intestine.  We utilised apical administration and 639 
the reductions in Isc we observed occurred within the same time frame as other apically located L 640 
cell Gαq-coupled receptors, some activated by water-soluble compounds (Joshi et al. 2013, Forbes 641 
et al. 2015, Alamshah et al. 2016) thus indicating apical receptors. 642 
GW9508 is reported to act via FFA1 and FFA4 with 100x higher affinity for FFA1 than FFA4 643 
(Briscoe et al. 2006).  GW9508 is a dual agonist at the FFA1 and FFA4 and this may explain its 644 
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slightly greater efficacy than more selective agonists we used.  We found that the selective FFA1 645 
and FFA4 agonists exhibited a similar potency which was more potent than the potency of 646 
GW9508.  Both FFA4 agonists, Metabolex-36 and AZ423 have >100-fold higher selectivity for 647 
FFA4 in comparison to the FFA1.  This phenomenon of higher potency but lower efficacy has 648 
been observed previously with a GPR119 agonist, PSN-GPR119 (Patel et al. 2014) and may 649 
indicate acute receptor desensitisation. 650 
FFA1 agonists are preferentially Gαq/11-linked and recent evidence suggests that 'Gαq/11-only' 651 
FFA1 agonists (e.g. TAK-875) stimulate the release of incretin hormones, GLP-1 and GIP, with 652 
reduced efficacy compared to FFA1 agonists that signal via Gαq/11 and Gαs pathways; to cause a 653 
more robust release of GLP-1 and GIP (Hauge et al. 2015).  Our FFA1 agonists appear to be 654 
Gαq/11-coupled preferentially as mucosal responses were transient in comparison with Gαs-coupled 655 
L cell signalling e.g. GPR119 or MC4 (Cox et al. 2010, Panaro et al. 2014).   656 
 657 
FFA1 antagonism reveals FFA1 mucosal and anti-motility tone and agonist-specificity.  658 
The FFA1 antagonists, ANT825 and GW1100 revealed, for the first time, a degree of endogenous 659 
FFA1 tonic activity in colonic mucosa.  The degree of tonic activity was similar to that observed 660 
with the MC4 receptor antagonist, HS014 (3.6 μA.cm-2) (Panaro et al. 2014).  Since endogenous 661 
FFA1 and MC4 agonism stimulates PYY release from L cells, blockade of these receptors inhibits 662 
endogenous PYY release.  Crivellato et al (2002) demonstrated that enteroendocrine cells in 663 
mouse colon undergo piecemeal degranulation, hormone release that may be related to the tonic 664 
activity we observe in mucosa.  Endogenous lipids, natural ligands of the FFA1 (Itoh et al. 2003) 665 
may be responsible for the observed tonic activity via FFA1.  666 
The potency of the FFA1 competitive antagonist, ANT825 was not dissimilar from its potency 667 
(pEC50 of 6.8) obtained in a human embryonic kidney 293 cell line expressing human FFA1, 668 
measuring inositol monophosphate (Waring 2015).  We found GW1100 (pIC50 of 5.99; (Briscoe et 669 
al. 2006)) abolished TUG424 responses but not TUG891 responses, showing FFA1 selectivity as 670 
seen previously (Briscoe et al. 2006).  Like GW1100, ANT825 abolished FFA1 responses but 671 
both FFA1 antagonists’ also partially inhibited GW9508 responses, indicating that at this 672 
concentration (1 µM); GW9508 exerts a dual agonism via FFA1 and most likely FFA4.  Briscoe et 673 
al (2006) revealed that GW1100 had no effect on the ability of GW9508 to activate FFA4. We 674 
conclude that GW9508 is a dual FFA1 and FFA4 agonist.   675 
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FFA1 (TUG424, TAK-875) and FFA4 (TUG891, Metabolex-36) agonists attenuated colonic 676 
motility in vitro to a similar degree as seen previously with MC4 receptor activation and GPR119 677 
agonism (Panaro et al. 2014).  They decreased colonic motility presumably via the release of 678 
PYY, which mediates the colonic brake.  Pretreatment with the FFA1 antagonist, GW1100 679 
revealed basal colonic mucosal tone (as seen with Ussing chamber studies) indicative of 680 
endogenous FFA1 activity.  In the presence of the FFA1 antagonist GW1100, the colonic brake 681 
induced by the FFA1 agonist (TUG424) was disinhibited and therefore colonic transit increased 682 
whereas transit induced by FFA4 agonist (TUG891) remained unaffected, showing selectivity of 683 
the FFA1 agonist. 684 
As the FFA1 agonist, TAK875 and the FFA4 agonist, Metabolex-36 slowed transit in vitro; we 685 
investigated their ability to slow transit in vivo.  Following the overnight fast, plasma glucose 686 
levels were reduced to 5 mM.   However, we established that FFA1 and FFA4 signalling is 687 
unchanged at 5 mM compared with 11.1 mM glucose as seen previously for GPR119 agonism 688 
(Patel et al. 2014).  Metabolex-36 slowed colonic transit significantly presumably via PYY, 689 
whereas TAK-875 failed to show significant inhibition of bead colonic transit when administered 690 
orally or via i.p. injection.   This apparent lack of efficacy may be due to TAK-875's partial 691 
agonism or its administration as a suspension.  In our in vitro transit studies, the isolated colon is 692 
severed from the central nervous system (CNS) and TAK-875 acts directly upon colonic FFA1 693 
receptors.  In the in vivo model, it’s possible that the ability of TAK-875 to release PYY is not 694 
sufficient to alter colonic motility, with the added complication of modulatory CNS pathways.  In 695 
addition, there are concerns in the literature that isoflurane interferes with GI transit.   In 2005, 696 
Torjman and colleagues reported that 6 min exposure to isoflurane in rats slows UGIT by 50% 697 
(Torjman et al. 2005).  In our study, mice received a 2 min exposure of isoflurane 1 h after the 698 
drug, vehicle or positive control were administered, followed by bead insertion and excretion.  699 
Therefore, we conclude that this brief exposure of isoflurane in our protocol (at the time of 700 
maximal drug exposure) should have minimal effect on colonic motility.  Furthermore, we note 701 
that there are no differences in colonic transit rates between different vehicle controls (oral gavage 702 
vs i.p.) in this study, compared with those in a previous investigation (Forbes et al. 2012).   703 
Unexpectedly, Metabolex-36 was pro-motile in the upper intestine.  FFA4 is expressed on I cells, 704 
K cells and L cells causing release of CCK, GIP and PYY (and GLP-1) respectively, via Gαq-705 
signalling (Iwasaki et al. 2015, Hirasawa et al. 2005, Tanaka et al. 2008).  These peptides inhibit 706 
gastric emptying and small intestinal transit and additionally, PYY is responsible for both ileal and 707 
colonic brakes (Spiller et al. 1984, Spiller et al. 1988).  However, recently FFA4 has been 708 
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identified in gastric ghrelin and somatostatin cells, signalling via Gαi proteins to inhibit peptide 709 
release (Engelstoft et al. 2013, Egerod et al. 2015).  Somatostatin is known to inhibit motility and 710 
increase the interval between migrating myoelectric complexes (MMC), therefore slowing transit. 711 
We hypothesised that Metabolex-36 increased intestinal motility by inhibiting somatostatin release 712 
and tested this possibility with the SST2 antagonist, CYN 154806 at an effective dose used 713 
previously in rat small intestine, in vivo (Booth et al. 2001).  However, CYN 154806 was 714 
ineffective (at 3 mg/kg) and we conclude that either the antagonist dose used was too low in the 715 
mouse, or Metabolex-36 produces a pro-motile effect via an alternative FFA4 mechanism.   716 
 717 
PYY-Y1 but not PYY-Y2 mediation of FFA1 and FFA4 signalling in mouse colonic mucosa 718 
FFA1 and FFA4 agonist responses in the mouse colon were Y1 receptor mediated.  Additionally, 719 
these responses were unaffected by TTX indicating a predominantly epithelial origin for FFA1 720 
and FFA4 activity, not involving TTX-sensitive submucosal neurons.  The degree of antisecretory 721 
tone mediated by the Y1 and Y2 receptors was similar to that shown previously in mouse colon 722 
(Hyland et al. 2003, Tough et al. 2011).  The FFA1 and FFA4 signalling in colonic mucosa are 723 
mediated by endogenous PYY acting on local epithelial Y1 receptors.  The epithelial Y1 mediation 724 
and lack of any Y2 (neuronal) involvement is consistent with our previous findings for other L 725 
cell-enriched receptors e.g. MC4 (Panaro et al. 2014), GPR119 (Patel et al. 2014), FFA2 (Forbes 726 
et al. 2015) and the calcium-sensing receptor (Joshi et al. 2013). There appears to be no GLP-1 727 
mediation of FFA1 and FFA4 responses in this study. GLP-1 has a half-life of 1.5 min which 728 
limits the ability to detect its response, if any.  Additionally, we have discovered that the GLP-1 729 
response can vary across the colon, with largest GLP-1 responses observed in the ascending colon 730 
and smallest in the descending colon (Tough et al. 2017).  Here we have used descending colon 731 
and in combination with the short half-life of GLP-1, this may explain why we do not see a GLP-1 732 
mediated response.  733 
 734 
FFA1 and FFA4 responses in mouse colon mucosa are glucose-sensitive  735 
Our studies demonstrate for the first time that activation of FFA1 and FFA4 responses in native 736 
tissues are glucose-sensitive as seen in previous investigations of L cell-specific activation by 737 
GPR119 (Cox et al. 2010), MC4 receptor (Panaro et al. 2014), the activation of the calcium-738 
sensing receptor by L-glutamine (Joshi et al. 2013) and FFA2 agonism (Forbes et al. 2015). 739 
  30 
Theoretically these agonists should not therefore cause hypoglycaemia in vivo, a disadvantage of 740 
certain anti-diabetic drugs currently on the market.  FFA1 and FFA4 receptors are currently 741 
clinically favourable targets as they are not only co-expressed in GI L cells but differentially 742 
expressed in the pancreas.  FFA1 is expressed in pancreatic β-cells (Itoh et al. 2003) and FFA4 has 743 
recently been discovered in somatostatin-containing delta cells (Stone et al. 2014).  PYY and 744 
GLP-1 released from the L cells should enhance satiety (an advantage for patients with associated 745 
obesity) and elevate insulin release respectively via activation of GLP-1 receptors on pancreatic β 746 
cells.  Furthermore, an FFA1 agonist could simultaneously directly elevate insulin release after a 747 
meal. This combination of indirect and direct FFA1 effects should improve glucose tolerance 748 
without hypoglycaemia.  749 
 750 
Final conclusions 751 
We have shown that selective FFA1 and FFA4 agonism is PYY-Y1 receptor mediated and 752 
glucose-sensitive in mouse descending colon mucosa. These compounds would limit potential 753 
hypoglycaemia, a side effect of certain commercially available anti-diabetic drugs.  ANT825 and 754 
GW1100 revealed tonic FFA1 activity and the possibility of FFA1 endogenous ligands causing 755 
PYY release. Furthermore, we have shown for the first time that agonism of FFA1 and FFA4 756 
inhibits colonic transit in vitro and FFA4 agonism induces regional differences in transit in vivo.  757 
In colonic L cells agonism of FFA4 is presumably Gαq-mediated and leads to antisecretory 758 
mucosal responses that slows colonic transit, but leads to upper GI pro-motile activity in vivo in 759 
the mouse, which remains unresolved.  FFA1 and FFA4 co-agonism may be beneficial 760 
therapeutically and would more closely mimic the combinatorial activity of long chain fatty acids 761 
in the diet.  762 
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